NASDAQ:SDGR

Schrödinger Competitors

$61.45

+0.21 (+0.34 %)

(As of 05/17/2021 12:00 AM ET)

Add

Compare

Today's Range

$59.00

▼

$61.68

50-Day Range

$59.02

▼

$78.57

52-Week Range

$46.27

▼

$117.00

Volume547,644 shs

Average Volume1.04 million shs

Market Capitalization$4.30 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Schrödinger (NASDAQ:SDGR) Vs. ELAN, ALNY, ZLAB, BMRN, GRFS, and RDY

Should you be buying SDGR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Schrödinger, including Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), and Dr. Reddy's Laboratories (RDY).

Schrödinger vs. Elanco Animal Health Stock

Schrödinger (NASDAQ:SDGR) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Elanco Animal Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
Elanco Animal Health	1	3	9	0	2.62

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Elanco Animal Health has a consensus target price of $33.1364, indicating a potential downside of 5.35%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Elanco Animal Health.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Elanco Animal Health's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
Elanco Animal Health	-8.45%	3.43%	2.04%

Earnings & Valuation

This table compares Schrödinger and Elanco Animal Health's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
Elanco Animal Health	$3.07 billion	5.39	$67.90 million	$1.06	33.03

Elanco Animal Health has higher revenue and earnings than Schrödinger.

Summary

Elanco Animal Health beats Schrödinger on 8 of the 11 factors compared between the two stocks.

Schrödinger vs. Alnylam Pharmaceuticals Stock

Schrödinger (NASDAQ:SDGR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Alnylam Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
Alnylam Pharmaceuticals	0	8	8	0	2.50

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Alnylam Pharmaceuticals has a consensus target price of $168.7333, indicating a potential upside of 24.17%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Alnylam Pharmaceuticals.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
Alnylam Pharmaceuticals	-222.19%	-65.96%	-31.38%

Earnings & Valuation

This table compares Schrödinger and Alnylam Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
Alnylam Pharmaceuticals	$219.75 million	72.69	$-886,120,000.00	($8.11)	-16.76

Schrödinger has higher earnings, but lower revenue than Alnylam Pharmaceuticals.

Summary

Schrödinger beats Alnylam Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Schrödinger vs. Zai Lab Stock

Schrödinger (NASDAQ:SDGR) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Zai Lab, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
Zai Lab	0	0	5	0	3.00

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Zai Lab has a consensus target price of $197.8460, indicating a potential upside of 28.48%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Zai Lab.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 81.3% of Zai Lab shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Zai Lab's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
Zai Lab	N/A	N/A	N/A

Earnings & Valuation

This table compares Schrödinger and Zai Lab's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
Zai Lab	$12.98 million	1,123.31	$-195,070,000.00	($3.03)	-50.82

Schrödinger has higher revenue and earnings than Zai Lab.

Summary

Zai Lab beats Schrödinger on 7 of the 10 factors compared between the two stocks.

Schrödinger vs. BioMarin Pharmaceutical Stock

Schrödinger (NASDAQ:SDGR) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and BioMarin Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
BioMarin Pharmaceutical	0	7	10	0	2.59

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. BioMarin Pharmaceutical has a consensus target price of $118.20, indicating a potential upside of 52.83%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Schrödinger.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
BioMarin Pharmaceutical	45.74%	4.34%	2.84%

Earnings & Valuation

This table compares Schrödinger and BioMarin Pharmaceutical's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
BioMarin Pharmaceutical	$1.70 billion	8.29	$-23,850,000.00	$0.07	1,104.86

BioMarin Pharmaceutical has higher revenue and earnings than Schrödinger.

Summary

BioMarin Pharmaceutical beats Schrödinger on 9 of the 11 factors compared between the two stocks.

Schrödinger vs. Grifols Stock

Schrödinger (NASDAQ:SDGR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Grifols, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
Grifols	0	3	5	0	2.63

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Given Schrödinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrödinger is more favorable than Grifols.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Grifols' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
Grifols	12.79%	10.65%	4.79%

Earnings & Valuation

This table compares Schrödinger and Grifols' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
Grifols	$5.71 billion	2.25	$700.16 million	$1.17	15.97

Grifols has higher revenue and earnings than Schrödinger.

Summary

Grifols beats Schrödinger on 6 of the 10 factors compared between the two stocks.

Schrödinger vs. Dr. Reddy's Laboratories Stock

Schrödinger (NASDAQ:SDGR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Schrödinger and Dr. Reddy's Laboratories, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0	1	3	0	2.75
Dr. Reddy's Laboratories	0	0	3	0	3.00

Schrödinger presently has a consensus target price of $84.00, indicating a potential upside of 36.70%. Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential downside of 2.78%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Dr. Reddy's Laboratories.

Insider and Institutional Ownership

41.3% of Schrödinger shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Schrödinger and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrödinger	-19.92%	-7.25%	-5.33%
Dr. Reddy's Laboratories	8.23%	16.33%	10.79%

Earnings & Valuation

This table compares Schrödinger and Dr. Reddy's Laboratories' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$85.54 million	50.30	$-24,570,000.00	N/A	N/A
Dr. Reddy's Laboratories	$2.32 billion	5.17	$259 million	$2.79	25.81

Dr. Reddy's Laboratories has higher revenue and earnings than Schrödinger.

Summary

Dr. Reddy's Laboratories beats Schrödinger on 7 of the 10 factors compared between the two stocks.